CME — CME Group Inc.

Momentum is positive after Q2 2026 record revenue of $1.71B, record market data revenue of $238M, and a 23% YoY jump in July volume. But the sell-side is mixed: consensus is Hold, Deutsche Bank recently downgraded to Hold, and even the FMP consensus target of $299 implies only ~6% upside from $280.94. Bulls and bears are balancing strong franchise quality against full valuation and decelerating trailing growth.

Over the last 12 quarters CME's revenue is up but lumpy: revenue grew from $1.34B in Q3 2023 to $1.71B in Q2 2026, with a record $1.88B in Q1 2026 followed by a normal seasonal dip in Q2. YoY revenue growth slowed from ~14% in Q1 2026 to just +0.8% in Q2 2026, and Q2 operating cash flow fell 10.5% YoY. Margins remain excellent — Q2 operating margin ~65%, net margin ~61% — and Q2 EPS grew 2.5% YoY to $2.88. This is more quarterly volume noise than structural deterioration, but the trailing growth trend is genuinely flattening.

At $280.94 as of 2026-08-27, CME trades at 23.7x TTM EPS and roughly 22.9x next-FY EPS of $12.265. That is below its 5-year average P/E of 25.2x, but P/S of 14.9x is above the 5-year average of 14.3x, and a TTM PEG of 1.64 is not cheap for a business growing EPS only ~3-4%. The 4.4% dividend is attractive, but the ~95% payout ratio limits reinvestment. Net read: fair-to-slightly-rich, with no meaningful margin of safety.

At $280.94 the market is paying 23.7x TTM earnings for a business whose forward EPS estimate is only ~3% above TTM EPS. That means CME is priced as a reliable, slow-growing toll booth, not a high-growth compounder. If July's 23% YoY volume acceleration drives Q3 beats, the stock can push toward the $299 consensus target. If volumes normalize or rate-cut expectations reduce hedging activity, the multiple leaves little cushion.

As of 2026-08-27, RSI stood at 68.2 — elevated but not quite overbought. Price was 4.4% above its 20-day SMA, 10.9% above its 50-day SMA, and only 0.8% above its 200-day SMA, indicating a recent breakout from a flat-to-weak trend. Short-term momentum is stretched, so chasing at $280.94 is unattractive; a pullback toward the 50-day SMA (~$253) or an RSI retreat below 60 would offer a better entry.

• Central bank rate paths: continued hedging demand in rates and FX supports baseline volumes, but a shift to easier policy could reduce interest-rate contract volumes.
• Macro volatility: CME volume spikes with market stress; a calm, low-vol regime would pressure trading volumes.
• Regulatory capital and margin rules: stricter clearinghouse requirements raise costs but reinforce CME's role as the trusted central clearer.
• Competition from decentralized/offshore crypto perpetuals: a long-term structural threat, though management argues institutional demand still favors cleared futures.
• Product expansion into market data, single-stock futures, and factor futures: diversifies revenue beyond core interest-rate products.

• September 21, 2026: launch of E-mini Equity Factor futures (Growth, Value, Quality, Momentum, Low Volatility, Dividend 100).
• Q4 2026: Treasury Link and financially-settled Wind Power futures deployments.
• October 28, 2026: Q3 earnings; sustained strength from July's 23% YoY ADV growth would be a positive catalyst.
• March 2027: CEO transition to Lynne Fitzpatrick; continued market data revenue streak (33 consecutive quarters of growth) is a tailwind.

• Rate-cut cycle cools hedging demand in interest-rate and FX derivatives, reducing core volumes.
• High payout ratio (~95%) leaves little earnings buffer if volumes or margins dip.
• Analyst sentiment is mixed: 5 sells, 18 holds, 14 buys; consensus target offers only ~6% upside.
• Long-term competitive pressure from crypto perpetual venues and alternative trading architectures.
• Management transition and net insider selling over the trailing year add caution around capital stewardship.

CME is a high-quality exchange franchise with real pricing power, 65% operating margins, and a 4.4% dividend — but at $280.94 most of that quality is already in the price. The deterministic score's Weak Fundamentals label is too harsh on the franchise but directionally correct on the recent growth inflection. I would not chase the stock at RSI ~68; a better entry is closer to $250–260 or after a confirmed Q3 volume/earnings beat.

Calculated by applying a justified forward P/E of 24.0x to next-FY EPS of $12.265 — a slight discount to CME's 5-year average P/E of 25.2x to reflect the current revenue and cash-flow deceleration, while still giving credit for its high-margin exchange moat, durable dividend, and new product optionality.